Your session is about to expire
← Back to Search
hypofractionation for Prostate Cancer
Study Summary
This trial is designed to determine whether high risk prostate cancer patients can be safely treated with a shorter, more intense radiation therapy regimen. 3D-Conformal Radiotherapy (3D-CRT) or Intensity Modulated Radiotherapy (IMRT) will be used to deliver the required radiation dose. Patients will also receive 28 months of androgen deprivation therapy (LHRH agonist). The primary outcome of the study is the acute and delayed toxicity and the secondary outcomes include biochemical failure, prostate specific mortality rate, bone metastases free survival, the prognostic and predictive value of several biological variables. It is planned to recruit 250
- Prostate Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any unfilled vacancies for people who want to participate in this research?
"The latest information from clinicaltrials.gov shows that this study is not currently recruiting participants. The trial was originally posted on 1/1/2012 and was last updated on 10/19/2020. However, there are 1628 other studies that are actively seeking patients right now."
Are there any dangers associated with hypofractionation?
"There is pre-existing data that hypofractionation is safe and effective, thus it received a score of 3."
Do you know of any other places in North America where this clinical trial is taking place?
"The 12 hospitals conducting this clinical trial are Hôpital de la Cité-de-la-santé de Laval in Laval, CHUM-Notre Dame in Montreal, Centre de santé Rimouski-Neigette in Rimouski, and 9 other locations."
Share this study with friends
Copy Link
Messenger